Fas Ligand (Human Recombinant)

<strong>Fas Ligand (Human Recombinant)</strong>_x000D_ <strong>Catalog number:</strong> B2010566_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 10 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> na_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> molecular in the study of various cellular systems_x000D_ <strong>Storage:</strong> -20C_x000D_ <strong>Keywords:</strong> CD95L, CD178_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Rieux-Laucat F, Magérus-Chatinet A, Neven B. The Autoimmune_x000D_ Lymphoproliferative Syndrome with Defective FAS or FAS-Ligand Functions. J Clin_x000D_ Immunol. 2018 Jul;38(5):558-568._x000D_ _x000D_ 2: Sato Y, Yoshino H, Tsuruga E, Kashiwakura I. Fas Ligand Enhances Apoptosis of_x000D_ Human Lung Cancer Cells Cotreated with RIG-I-like Receptor Agonist and_x000D_ Radiation. Curr Cancer Drug Targets. 2020;20(5):372-381._x000D_ _x000D_ 3: Modiano JF, Bellgrau D. Fas ligand based immunotherapy: A potent and_x000D_ effective neoadjuvant with checkpoint inhibitor properties, or a systemically_x000D_ toxic promoter of tumor growth? Discov Med. 2016 Feb;21(114):109-16._x000D_ _x000D_ 4: Guégan JP, Legembre P. Nonapoptotic functions of Fas/CD95 in the immune_x000D_ response. FEBS J. 2018 Mar;285(5):809-827._x000D_ _x000D_ 5: Glukhova XA, Trizna JA, Proussakova OV, Gogvadze VG, Beletsky IP._x000D_ Dephosphorylation of Fas_ligand and caveolin-1 is a prerequisite step in Fas-_x000D_ ligand - caveolin-1 complex formation and cell death stimulation. Cell Signal._x000D_ 2020 Jun;70:109590._x000D_ _x000D_ 6: Owen-Schaub L, Chan H, Cusack JC, Roth J, Hill LL. Fas and Fas ligand_x000D_ interactions in malignant disease. Int J Oncol. 2000 Jul;17(1):5-12._x000D_ _x000D_ 7: Puppo F, Ghio M, Contini P, Mazzei C, Indiveri F. Fas, Fas_ligand,and_x000D_ transfusion immunomodulation. Transfusion. 2001 Mar;41(3):416-8._x000D_ _x000D_ 8: Wang T, Lian Y. The relationship between Fas and Fas_ligand gene polymorphism_x000D_ and preeclampsia risk. Biosci Rep. 2019 Feb 15;39(2):BSR20181901._x000D_ _x000D_ 9: O'Brien DI, Nally K, Kelly RG, O'Connor TM, Shanahan F, O'Connell J._x000D_ Targeting the Fas/Fas_ligand pathway in cancer. Expert Opin Ther Targets. 2005_x000D_ Oct;9(5):1031-44._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/17363955/">10: Murata J, Abe R. Soluble Fas ligand: is it a critical mediator of toxic_x000D_ epidermal necrolysis and Stevens-Johnson syndrome? J Invest Dermatol. 2007_x000D_ Apr;127(4):744-5. </a>_x000D_ _x000D_ <strong>Products Related to Fas Ligand (Human Recombinant)</strong><a href="https://moleculardepot.com/product-category/Proteins/">: Proteins</a>